ナノメディシンの世界市場：ナノ分子タイプ別、ナノ粒子タイプ別、用途別、疾病適応別、地域別、競合予測と機会、2027年

世界のナノメディシンの市場規模は、予測期間である2023年～2027年に8.28%のCAGRで拡大し、2026年には2,426億5,519万米ドルに達すると予測されています。

当レポートでは、世界のナノメディシン市場について調査し、市場の概要とともに、ナノ分子タイプ別、ナノ粒子タイプ別、用途別、疾病適応別、地域別の動向、競合動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のナノメディシン市場に対するCOVID-19の影響

第5章 顧客の声

第6章 世界のナノメディシン市場の見通し

• 市場規模と予測
• 市場シェアと予測
  • ナノ分子タイプ別（ナノ粒子、ナノシェル、ナノデバイス、ナノチューブ）
  • 用途別（ドラッグデリバリー、ワクチン、画像診断、再生医療、その他）
  • 疾病適応別（腫瘍性疾患、感染症、整形外科疾患、心血管疾患、その他）
  • 企業別（2021年）
  • 地域別
• 市場マップ

第7章 北米のナノメディシン市場の見通し

• 市場規模と予測
• 市場シェアと予測
• 北米：国別分析

第8章 欧州のナノメディシン市場の見通し

• 市場規模と予測
• 市場シェアと予測
• 欧州：国別分析

第9章 アジア太平洋のナノメディシン市場の見通し

• 市場規模と予測
• 市場シェアと予測
• アジア太平洋：国別分析

第10章 南米のナノメディシン市場の見通し

• 市場規模と予測
• 市場シェアと予測
• 南米：国別分析

第11章 中東・アフリカのナノメディシン市場の見通し

• 市場規模と予測
• 市場シェアと予測
• 中東・アフリカ：国別分析

第12章 市場力学

• 促進要因
• 課題

第13章 市場の動向と発展

第14章 競合情勢

• Pfizer Inc.
• Janssen Pharmaceuticals
• Sanofi S.A.
• Amgen Inc.
• Moderna, Inc.
• Novo Nordisk A/S
• Genentech, Inc
• Celgene Corporation
• Vifor Pharma Ltd.
• Teva Pharmaceutical Industries Ltd.

第15章 戦略的推奨事項

List of Figures

• Figure 1: Global Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 2: Global Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 3: Global Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 4: Global Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 5: Global Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 6: Global Nanomedicine Market Share, By Region, By Value, 2017-2027F
• Figure 7: Global Nanomedicine Market Share, By Company, By Value, 2021
• Figure 8: Global Nanomedicine Market Map, By Nanomolecule Type, Market Size (USD Million) & Growth Rate (%), 2021
• Figure 9: North America Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 10: North America Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 11: North America Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 12: North America Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 13: North America Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 14: North America Nanomedicine Market Share, By Country, By Value, 2017-2027F
• Figure 15: United States Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 16: United States Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 17: United States Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 18: United States Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 19: United States Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 20: Canada Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 21: Canada Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 22: Canada Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 23: Canada Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 24: Canada Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 25: Mexico Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 26: Mexico Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 27: Mexico Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 28: Mexico Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 29: Mexico Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 30: Europe Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 31: Europe Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 32: Europe Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 33: Europe Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 34: Europe Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 35: Europe Nanomedicine Market Share, By Country, By Value, 2017-2027F
• Figure 36: Germany Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 37: Germany Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 38: Germany Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 39: Germany Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 40: Germany Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 41: France Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 42: France Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 43: France Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 44: France Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 45: France Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 46: United Kingdom Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 47: United Kingdom Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 48: United Kingdom Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 49: United Kingdom Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 50: United Kingdom Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 51: Italy Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 52: Italy Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 53: Italy Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 54: Italy Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 55: Italy Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 56: Spain Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 57: Spain Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 58: Spain Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 59: Spain Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 60: Spain Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 61: Denmark Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 62: Denmark Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 63: Denmark Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 64: Denmark Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 65: Denmark Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 66: Middle East & Africa Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 67: Middle East & Africa Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 68: Middle East & Africa Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 69: Middle East & Africa Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 70: Middle East & Africa Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 71: Middle East & Africa Nanomedicine Market Share, By Country, By Value, 2017-2027F
• Figure 72: China Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 73: China Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 74: China Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 75: China Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 76: China Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 77: Japan Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 78: Japan Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 79: Japan Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 80: Japan Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 81: Japan Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 82: India Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 83: India Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 84: India Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 85: India Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 86: India Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 87: Australia Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 88: Australia Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 89: Australia Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 90: Australia Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 91: Australia Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 92: South Korea Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 93: South Korea Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 94: South Korea Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 95: South Korea Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 96: South Korea Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 97: Malaysia Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 98: Malaysia Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 99: Malaysia Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 100: Malaysia Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 101: Malaysia Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 102: Vietnam Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 103: Vietnam Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 104: Vietnam Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 105: Vietnam Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 106: Vietnam Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 107: South America Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 108: South America Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 109: South America Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 110: South America Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 111: South America Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 112: South America Nanomedicine Market Share, By Country, By Value, 2017-2027F
• Figure 113: Brazil Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 114: Brazil Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 115: Brazil Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 116: Brazil Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 117: Brazil Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 118: Argentina Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 119: Argentina Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 120: Argentina Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 121: Argentina Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 122: Argentina Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 123: Colombia Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 124: Colombia Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 125: Colombia Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 126: Colombia Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 127: Colombia Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 128: Middle East & Africa Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 129: Middle East & Africa Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 130: Middle East & Africa Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 131: Middle East & Africa Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 132: Middle East & Africa Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 133: Middle East & Africa Nanomedicine Market Share, By Country, By Value, 2017-2027F
• Figure 134: Turkey Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 135: Turkey Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 136: Turkey Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 137: Turkey Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 138: Turkey Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 139: Israel Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 140: Israel Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 141: Israel Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 142: Israel Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 143: Israel Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 144: South Africa Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 145: South Africa Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 146: South Africa Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 147: South Africa Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 148: South Africa Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 149: Saudi Arabia Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 150: Saudi Arabia Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 151: Saudi Arabia Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 152: Saudi Arabia Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 153: Saudi Arabia Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 154: UAE Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 155: UAE Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 156: UAE Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 157: UAE Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 158: UAE Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
• Figure 159: Kuwait Nanomedicine Market Size, By Value (USD Million), 2017-2027F
• Figure 160: Kuwait Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
• Figure 161: Kuwait Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
• Figure 162: Kuwait Nanomedicine Market Share, By Application, By Value, 2017-2027F
• Figure 163: Kuwait Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F

The global nanomedicine market is expected to grow at an impressive CAGR of 8.28% in the forecast period, 2023-2027, to reach USD242655.19 million by 2027. The market is driven by the factors such as the growing healthcare expenditure and increased demand for personalized medicines. The massive prevalence of chronic and lifestyle disorders such as cancer and cardiovascular diseases across the globe is accelerating the application of nanomedicine in various healthcare applications. Also, the high-end investments in research and development activities by public and private players to find novel solutions for drug delivery and increase the effectiveness of drugs are expected to create lucrative growth opportunities for the global nanomedicine market in the forecast period.

Nanomedicines are considered very effective in treating chronic diseases such as cancer, dementia, and diabetes as they fuel the metabolism of medications in the body. They deliver the drugs at the target site in the right proportion. The market's availability of nanomedical products such as DNA probes, nanosensors, and nanoparticle-based imaging agents is increasing the demand. However, the high cost associated with the nanomedicine manufacturing process and research and development activities may hinder the global nanomedicine market in the forecast period.

The global nanomedicine market is divided into nano molecule type, nanoparticles type, application, disease indication, regional distribution, and competitive landscape. Based on application, the nanomedicine market is divided into drug delivery, vaccines, diagnostic imaging, regenerative medicine, and others. Drug delivery applications dominated the market in 2021 and captured 30.23% of the overall market share. This segment is expected to maintain its dominance over the next five years. The rise in awareness about the benefits of nanomedicine in drug delivery applications and the increased prevalence of diseases drives the demand for nanomedicines for drug delivery applications.

The major market players operating in the global nanomedicine market are Pfizer Inc., Janssen Pharmaceuticals, Sanofi S.A., Amgen Inc., Moderna, Inc., Novo Nordisk A/S, Genentech, Inc., Celgene Corporation, Vifor Pharma Group, Teva Pharmaceutical Industries Ltd., among others.

Years considered for this report:

Historical Years: 2017-2020

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2023-2027

Objective of the Study:

• To analyze the historical growth and the market size of the global nanomedicine market from 2017 to 2021.
• To estimate and forecast the market size of the global nanomedicine market from 2023 to 2027 and growth rate until 2027.
• To classify and forecast the global nanomedicine market is divided into nanomolecule type, nanoparticles type, application, disease indication, regional distribution, and competitive landscape.
• To identify drivers and challenges for the global nanomedicine market.
• To examine competitive developments such as expansions, new product launches, mergers, and acquisitions, etc., in the global nanomedicine market.
• To conduct pricing analysis for the global nanomedicine market.
• To identify and analyze the profile of leading players operating in global nanomedicine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of leading nanomedicine manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the nanomedicine manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the nanomedicine manufacturers, distribution channels and presence of all major players operating in the global nanomedicine market all over the world.

TechSci Research calculated the global nanomedicine market size using a bottom-up approach, where data for various regions was recorded and forecasted for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

• Nanomedicine manufacturers/ suppliers/ distributors
• Government bodies such as regulating authorities and policy makers
• Organizations, forums, and alliances related to nanomedicine
• Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for industry stakeholders such as nanomedicine manufacturers, suppliers, distributors, and other stakeholders. The report would enable the stakeholders in strategizing investments and capitalizing on emerging market opportunities.

Report Scope:

In this report, global nanomedicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Nanomedicine Market, By Nanomolecule Type:

Nanoparticles

Nanoshells

Nanodevices

Nanotubes

• Nanomedicine Market, By Nanoparticles Type:

Polymer-based

Lipid-based

Nanocrystals

Inorganic

Others

• Nanomedicine Market, By Application:

Drug Delivery

Vaccines

Diagnostic Imaging

Regenerative Medicine

Others

• Nanomedicine Market, By Disease Indication:

Oncological Diseases

Infectious Diseases

Orthopedic Disorders

Cardiovascular Diseases

Others

• Nanomedicine Market, By Region:

North America

• United States
• Canada
• Mexico

Europe

• Germany
• France
• United Kingdom
• Italy
• Spain
• Denmark

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Malaysia
• Vietnam

South America

• Brazil
• Argentina
• Colombia

Middle East & Africa

• Turkey
• Israel
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global nanomedicine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Nanomedicine Market

5. Voice of Customer

• 5.1. Factors Increasing the demand for Nanomedicine
• 5.2. Preference, By Nanomolecule Type
• 5.3. Demand for Nanomedicine, By Indication
• 5.4. Brand Awareness

6. Global Nanomedicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
    • 6.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
  • 6.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
  • 6.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
  • 6.2.4. By Company (2021)
  • 6.2.5. By Region
• 6.3. Market Map

7. North America Nanomedicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
    • 7.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
  • 7.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
  • 7.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Nanomedicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Nanomolecule Type
      • 7.3.1.2.1.1. By Nanoparticle Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Disease Indication
  • 7.3.2. Canada Nanomedicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Nanomolecule Type
      • 7.3.2.2.1.1. By Nanoparticle Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Disease Indication
  • 7.3.3. Mexico Nanomedicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Nanomolecule Type
      • 7.3.3.2.1.1. By Nanoparticle Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Disease Indication

8. Europe Nanomedicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
    • 8.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
  • 8.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
  • 8.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Nanomedicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Nanomolecule Type
      • 8.3.1.2.1.1. By Nanoparticle Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Disease Indication
  • 8.3.2. France Nanomedicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Nanomolecule Type
      • 8.3.2.2.1.1. By Nanoparticle Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Disease Indication
  • 8.3.3. United Kingdom Nanomedicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Nanomolecule Type
      • 8.3.3.2.1.1. By Nanoparticle Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Disease Indication
  • 8.3.4. Italy Nanomedicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Nanomolecule Type
      • 8.3.4.2.1.1. By Nanoparticle Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Disease Indication
  • 8.3.5. Spain Nanomedicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Nanomolecule Type
      • 8.3.5.2.1.1. By Nanoparticle Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Disease Indication
  • 8.3.6. Denmark Nanomedicine Market Outlook
    • 8.3.6.1. Market Size & Forecast
      • 8.3.6.1.1. By Value
    • 8.3.6.2. Market Share & Forecast
      • 8.3.6.2.1. By Nanomolecule Type
      • 8.3.6.2.1.1. By Nanoparticle Type
      • 8.3.6.2.2. By Application
      • 8.3.6.2.3. By Disease Indication

9. Asia Pacific Nanomedicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
    • 9.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
  • 9.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
  • 9.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
  • 9.2.4. By Country
• 9.3. Asia Pacific: Country Analysis
  • 9.3.1. China Nanomedicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Nanomolecule Type
      • 9.3.1.2.1.1. By Nanoparticle Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Disease Indication
  • 9.3.2. Japan Nanomedicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Nanomolecule Type
      • 9.3.2.2.1.1. By Nanoparticle Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Disease Indication
  • 9.3.3. India Nanomedicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Nanomolecule Type
      • 9.3.3.2.1.1. By Nanoparticle Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Disease Indication
  • 9.3.4. Australia Nanomedicine Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Nanomolecule Type
      • 9.3.4.2.1.1. By Nanoparticle Type
      • 9.3.4.2.2. By Application
      • 9.3.4.2.3. By Disease Indication
  • 9.3.5. South Korea Nanomedicine Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Nanomolecule Type
      • 9.3.5.2.1.1. By Nanoparticle Type
      • 9.3.5.2.2. By Application
      • 9.3.5.2.3. By Disease Indication
  • 9.3.6. Malaysia Nanomedicine Market Outlook
    • 9.3.6.1. Market Size & Forecast
      • 9.3.6.1.1. By Value
    • 9.3.6.2. Market Share & Forecast
      • 9.3.6.2.1. By Nanomolecule Type
      • 9.3.6.2.1.1. By Nanoparticle Type
      • 9.3.6.2.2. By Application
      • 9.3.6.2.3. By Disease Indication
  • 9.3.7. Vietnam Nanomedicine Market Outlook
    • 9.3.7.1. Market Size & Forecast
      • 9.3.7.1.1. By Value
    • 9.3.7.2. Market Share & Forecast
      • 9.3.7.2.1. By Nanomolecule Type
      • 9.3.7.2.1.1. By Nanoparticle Type
      • 9.3.7.2.2. By Application
      • 9.3.7.2.3. By Disease Indication

10. South America Nanomedicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
    • 10.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
  • 10.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
  • 10.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nanomedicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Nanomolecule Type
      • 10.3.1.2.1.1. By Nanoparticle Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Disease Indication
  • 10.3.2. Argentina Nanomedicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Nanomolecule Type
      • 10.3.2.2.1.1. By Nanoparticle Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Disease Indication
  • 10.3.3. Colombia Nanomedicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Nanomolecule Type
      • 10.3.3.2.1.1. By Nanoparticle Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Disease Indication

11. Middle East and Africa Nanomedicine Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
    • 11.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
  • 11.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
  • 11.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
  • 11.2.4. By Country
• 11.3. Middle East and Africa: Country Analysis
  • 11.3.1. Turkey Nanomedicine Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Nanomolecule Type
      • 11.3.1.2.1.1. By Nanoparticle Type
      • 11.3.1.2.2. By Application
      • 11.3.1.2.3. By Disease Indication
  • 11.3.2. Israel Nanomedicine Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Nanomolecule Type
      • 11.3.2.2.1.1. By Nanoparticle Type
      • 11.3.2.2.2. By Application
      • 11.3.2.2.3. By Disease Indication
  • 11.3.3. South Africa Nanomedicine Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Nanomolecule Type
      • 11.3.3.2.1.1. By Nanoparticle Type
      • 11.3.3.2.2. By Application
      • 11.3.3.2.3. By Disease Indication
  • 11.3.4. Saudi Arabia Nanomedicine Market Outlook
    • 11.3.4.1. Market Size & Forecast
      • 11.3.4.1.1. By Value
    • 11.3.4.2. Market Share & Forecast
      • 11.3.4.2.1. By Nanomolecule Type
      • 11.3.4.2.1.1. By Nanoparticle Type
      • 11.3.4.2.2. By Application
      • 11.3.4.2.3. By Disease Indication
  • 11.3.5. UAE Nanomedicine Market Outlook
    • 11.3.5.1. Market Size & Forecast
      • 11.3.5.1.1. By Value
    • 11.3.5.2. Market Share & Forecast
      • 11.3.5.2.1. By Nanomolecule Type
      • 11.3.5.2.1.1. By Nanoparticle Type
      • 11.3.5.2.2. By Application
      • 11.3.5.2.3. By Disease Indication
  • 11.3.6. Kuwait Nanomedicine Market Outlook
    • 11.3.6.1. Market Size & Forecast
      • 11.3.6.1.1. By Value
    • 11.3.6.2. Market Share & Forecast
      • 11.3.6.2.1. By Nanomolecule Type
      • 11.3.6.2.1.1. By Nanoparticle Type
      • 11.3.6.2.2. By Application
      • 11.3.6.2.3. By Disease Indication

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends and Developments

14. Competitive Landscape

• 14.1. Pfizer Inc.
• 14.2. Janssen Pharmaceuticals
• 14.3. Sanofi S.A.
• 14.4. Amgen Inc.
• 14.5. Moderna, Inc.
• 14.6. Novo Nordisk A/S
• 14.7. Genentech, Inc
• 14.8. Celgene Corporation
• 14.9. Vifor Pharma Ltd.
• 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations